Clinical trials: Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), open to volunteers
- Condition Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
- Status Open to volunteers
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma
Window of Opportunity in Preserving Laryngeal Function Trial
This trial will study the safety and tolerability and disease survival rates in adult patients with recurrent/metastatic (R/M) HNSCC when treated with carboplatin or cisplatin, paclitaxel, and toripalimab.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Locally Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- WOLF (NCT07423078)
- Testing
- Toripalimab, Carboplatin, Cisplatin
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Matthew Spector
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma
This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).
- Conditions
- Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck Squamous Cell Carcinoma HNSCC
- Trial name
- NCT07659678
- Testing
- 64Cu-DOTA-ECL1i
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT07791745
- Testing
- Enlituo® + Anyouping® + PBC
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer
This Phase 2, open-label, multicenter study will evaluate the safety and preliminary efficacy of axelopran in combination with pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell…
- Trial name
- MORALE-HN01 (NCT07662720)
- Testing
- axelopran, Pembolizumab
- Volunteers
- 18 people
- Sponsor
- Glycyx Therapeutics
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Biomarker-positive EGFR/HER2- Expressing HNSCC
EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
This example Phase 1/2 protocol evaluates allogeneic EGFR/HER2 dual-target CAR-NK cells in adults with recurrent or metastatic HNSCC whose tumors meet protocol-defined co-expression criteria for EGFR and HER2/ERBB2.
- Trial name
- DUAL-HN (NCT07617805)
- Testing
- EGFR/HER2 Dual-Target CAR-NK Cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
There is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
- Trial name
- MRG003 (NCT07584499)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
The rationale for the new sequence of pulsed dose chemotherapy proposed in this trial is based on the hypotheses that current standard dosing of chemotherapy plus pembrolizumab ultimately suppresses the immune system and has a…
- Trial name
- NCT06052839
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dan Zandberg
HPV 16+ Recurrent or Metastatic Cancer, HNSCC
Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors
This is a phase I, open-label, dose escalation study to assess the safety, tolerability, efficacy and immunogenicity of TI-0093 injection in patients with recurrent or metastatic HPV-16 positive solid tumors.
- Conditions
- HPV 16+ Recurrent or Metastatic Cancer, HNSCC, Cervical Cancer
- Trial name
- NCT07081984
- Testing
- therapeutic tumor vaccine
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Therorna
Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer
Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.
This phase II interventional clinical trial aims to evaluate whether combining cetuximab and avelumab, after three cycles of platinum and taxane-based chemotherapy, can improve treatment outcomes for patients with recurrent or…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
- Trial name
- AVEC-119 (NCT06869473)
- Testing
- Cetuximab/avelumab
- Where
- 8 sites in Italy
- Volunteers
- 67 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest